Htg molecular diagnostics, inc (HTGM)
Balance Sheet / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14
Assets
Current assets:
Cash and cash equivalents

10,403

7,619

34,847

11,813

6,975

8,432

6,164

5,774

20,530

9,968

9,047

13,398

2,767

7,507

5,523

7,510

4,922

3,293

2,598

11,171

1,564

3,613

Short-term investments available-for-sale, at fair value

21,554

25,410

3,037

9,753

18,056

22,681

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Restricted cash

3,270

3,270

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Short-term investments available-for-sale, at fair value

-

-

-

-

-

-

27,613

34,955

25,125

-

-

-

2,610

4,304

11,097

15,405

25,231

28,201

28,711

18,456

-

-

Accounts receivable

1,202

3,164

3,933

3,981

3,349

5,012

3,361

3,481

2,836

6,356

3,159

1,550

1,196

1,377

591

1,911

574

716

696

554

852

801

Contract assets

-

-

-

-

-

-

-

-

167

-

-

-

-

-

-

-

-

-

-

-

-

-

Inventory, net of allowance of $39,403 at both March 31, 2020 and December 31, 2019

1,637

1,269

1,191

1,160

1,179

1,306

1,129

1,002

1,042

1,180

1,250

1,313

1,255

1,511

1,867

2,213

2,365

2,201

2,266

2,412

2,095

1,685

Prepaid insurance

-

-

-

-

-

-

-

-

-

-

-

-

-

-

215

236

61

-

393

531

-

20

Prepaid royalties

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

181

-

-

-

-

-

-

Prepaid expenses and other

525

633

854

1,069

557

519

688

845

464

443

527

468

368

433

226

256

264

445

223

236

122

91

Total current assets

38,594

41,367

43,864

27,778

30,118

37,951

38,956

46,060

50,167

17,948

13,985

16,730

8,198

15,134

19,521

27,714

33,420

34,858

34,889

33,361

4,634

6,212

Restricted cash, non-current

-

-

3,270

3,270

3,270

3,270

3,270

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Long-term investments available-for-sale, at fair value

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,620

2,603

7,766

14,412

-

-

Deferred offering costs

-

-

-

198

198

-

-

-

-

2

-

-

115

49

-

-

-

-

59

64

1,742

1,369

Deferred MidCap revolving loan costs

-

-

-

59

63

-

71

75

79

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease right-of-use assets

1,039

1,209

1,370

1,394

621

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Office equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

442

434

417

-

Leasehold improvements

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

252

242

236

-

Laboratory and manufacturing equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,127

2,682

2,331

-

Field equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

180

164

228

-

Software

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

140

140

140

-

Construction in progress

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

49

-

-

-

Total property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,193

3,664

3,354

-

Less: accumulated depreciation and amortization

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,365

2,190

2,065

-

Property and equipment, net

2,169

2,240

2,183

2,424

2,141

2,373

2,614

2,888

3,099

3,304

3,255

2,880

3,083

3,270

3,666

3,957

3,712

1,932

1,828

1,473

1,289

1,146

Other non-current assets

123

302

239

-

-

175

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total assets

41,926

45,119

50,927

35,124

36,412

43,771

44,912

49,024

53,345

21,256

17,240

19,611

11,397

18,454

23,188

31,672

39,753

39,394

44,544

49,312

7,666

8,728

Liabilities and stockholders’ equity
Current liabilities:
Accounts payable

1,666

1,662

3,016

3,357

1,414

1,849

1,867

1,306

2,216

2,438

2,693

1,343

1,193

761

1,117

1,607

2,231

724

966

1,192

878

948

Accrued liabilities

1,195

1,870

1,795

1,499

1,329

3,358

2,530

2,427

1,681

3,746

1,997

1,213

1,281

1,670

1,292

1,639

1,250

1,915

1,407

1,036

1,692

1,499

Contract liabilities - current

409

426

306

486

246

332

273

315

462

665

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue - current

-

-

-

-

-

-

-

-

-

-

780

637

255

335

283

183

25

47

32

28

32

41

NuvoGen obligation - current

1,093

1,152

1,327

1,286

1,232

1,290

593

605

560

496

460

509

557

604

582

762

743

543

362

181

-

-

MidCap Term Loan payable - current

280

-

1,166

583

-

-

-

-

-

5,793

7,363

6,668

6,527

6,389

6,254

6,122

5,993

3,059

2,017

998

1,644

813

Convertible note - current, net of debt issuance costs

2,991

2,987

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liabilities - current

696

758

773

682

478

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other current liabilities

36

41

34

63

79

186

199

199

202

200

228

224

241

258

270

264

234

29

-

-

-

-

Convertible notes, less discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,290

-

Total current liabilities

8,369

8,898

8,419

7,959

4,780

7,017

5,465

4,855

5,123

13,341

13,524

10,598

10,057

10,020

9,801

10,579

10,478

6,319

4,787

3,437

6,538

3,303

NuvoGen obligation - non-current, net of discount

4,265

4,498

4,650

5,044

5,292

5,702

6,684

6,970

7,268

7,520

7,709

7,811

7,914

8,017

8,169

8,119

8,267

8,415

8,544

8,674

8,804

8,677

Convertible note - non-current, net of debt issuance costs

-

-

2,984

2,980

2,977

2,974

2,970

2,967

2,964

2,960

-

-

-

-

-

-

-

-

-

-

-

-

Redeemable convertible preferred stock warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,079

730

MidCap Term Loan payable - non-current, net of discount and debt issuance costs

6,629

6,871

5,654

6,194

6,739

6,704

6,666

6,626

6,585

-

-

2,214

3,827

5,389

6,902

8,368

9,784

7,737

8,738

9,669

8,935

9,705

Operating lease liabilities - non-current

512

636

820

976

441

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other non-current liabilities

234

244

280

299

148

280

333

389

435

492

523

533

560

619

530

587

659

28

36

43

51

58

Total liabilities

20,012

21,149

22,811

23,454

20,381

22,679

22,120

21,809

22,376

24,315

21,757

21,159

22,359

24,047

25,403

27,654

29,189

22,500

22,107

21,825

25,408

22,475

Total redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

55,922

Total Redeemable Convertible Preferred Stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

56,844

-

Commitments and Contingencies (Note 15)

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

0

0

0

0

0

0

0

Stockholders’ equity:
Series A convertible preferred stock, $0.001 par value; 51,270 shares authorized as of March 31, 2020 and zero shares authorized as of December 31, 2019; 51,270 shares issued and outstanding as of March 31, 2020 and no shares issued and outstanding as of December 31, 2019

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

0

Common stock, $0.001 par value; 200,000,000 shares authorized at March 31, 2020 and December 31, 2019, 62,196,117 shares issued and outstanding at March 31, 2020 and 58,090,233 shares issued and outstanding at December 31, 2019

62

58

58

28

28

28

28

28

28

13

12

11

8

7

7

7

7

6

6

6

0

0

Additional paid-in-capital

-

-

193,953

-

-

172,086

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Additional paid-in-capital

197,578

194,234

-

172,831

172,386

-

171,663

171,246

170,898

131,492

128,114

125,703

110,452

110,081

107,786

107,527

107,226

106,569

-

-

-

-

Additional paid-in-capital (distributions in excess of capital)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

106,366

106,264

-

-1,426

Distributions in excess of capital

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,255

-

Treasury stock, no shares as of December 31, 2017 and 1,396 shares as of December 31, 2016

-

-

-

-

-

-

-

-

-

-

-

-

-

75

75

75

75

75

75

75

75

75

Accumulated other comprehensive income (loss)

48

-4

33

-2

6

-3

-8

-11

-11

-

-

-

-0

-1

-0

2

-2

-41

4

-

-

-

Accumulated deficit

-175,775

-170,317

-165,928

-161,188

-156,390

-151,019

-148,892

-144,048

-139,946

-134,566

-132,644

-127,263

-121,422

-115,606

-109,932

-103,444

-96,592

-89,566

-83,866

-78,709

-72,256

-68,168

Total stockholders’ equity

21,913

23,969

28,116

11,669

16,030

21,092

22,791

27,214

30,969

-3,059

-4,516

-1,547

-10,962

-5,592

-2,214

4,017

10,563

16,893

22,436

27,486

-74,586

-69,669

Total liabilities and stockholders' equity

41,926

45,119

50,927

35,124

36,412

43,771

44,912

49,024

53,345

21,256

17,240

19,611

11,397

18,454

23,188

31,672

39,753

39,394

44,544

49,312

7,666

8,728